Alumis (ALMS) has drawn fresh investor attention after reporting second quarter results alongside new Phase 3 ONWARD3 data for envudeucitinib in moderate-to-severe plaque psoriasis, capped by plans for a U.S. FDA filing.

The latest envudeucitinib data and FDA filing plan arrive after a mixed few weeks for Alumis, with the share price return down 8.3% over seven days and 12.2% over 30 days, yet still up 10.7% over 90 days and 182.6% year to date. The very large 1 year total shareholder return of 432.8% points to strong momentum over a longer horizon, even as recent earnings, including a net loss of $142.22 million in the second quarter, keep risk firmly in focus for investors weighing the current US$25.31 share price against the company’s progress.

If Alumis has sharpened your interest in high growth healthcare stories, this may be a useful moment to broaden your search with our screener of 44 healthcare AI stocks

Alumis is building a broad autoimmune pipeline around envudeucitinib, yet the stock has already delivered a very large 1 year return. The next step is to evaluate whether the current US$25.31 price still offers sufficient potential for new buyers.

Preferred Price-to-Book Multiple of 5.8x: Is It Justified?

With Alumis trading at a P/B ratio of 5.8x, the stock sits above the broader US Pharmaceuticals industry average of 2.7x at the last close of $25.31. That gap raises an important question for investors who are trying to understand what is already built into the current valuation.

The price to book ratio compares the market value of a company to its net assets on the balance sheet. For a clinical stage biopharma group like Alumis, which is currently unprofitable and focused on developing an autoimmune pipeline, a higher P/B can reflect expectations around future revenue potential that is not yet visible in earnings.

According to the data, Alumis is considered expensive relative to the broader US Pharmaceuticals industry on this metric, yet is in line with its closest peers where the average P/B is also 5.8x. That suggests investors are paying a premium versus the wider industry, while valuing Alumis roughly in line with similar companies. Given the company is forecast to remain unprofitable over the next three years, but revenue is forecast to grow 71.07% per year, the current P/B implies the market is already pricing in a meaningful degree of that expected top line expansion.

Result: Price-to-book of 5.8x (OVERVALUED)

However, investors also need to weigh execution risk around late stage trials and the ongoing net losses, which could tighten funding options if conditions become less supportive.

Next Steps

With sentiment on Alumis pulled between clinical promise and clear risks, it makes sense to review the details yourself and move promptly while information is fresh. To balance both sides of that story, take a closer look at the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Alumis?

If Alumis has sharpened your focus on healthcare, do not stop there. Use the Simply Wall Street Screener to spot other stocks that fit your style.

• Target dependable income by reviewing companies in the 10 dividend fortresses that might suit a portfolio focused on regular cash returns.
• Hunt for potential bargains using the screener containing 18 high quality undiscovered gems and see which lesser-known stocks line up with your quality and fundamentals checklist.
• Prioritise resilience by checking the 83 resilient stocks with low risk scores so you do not miss stocks that score well on downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.